In a preclinical model, treatment with anti-PD-1 or anti-PD-L1 was able to inhibit SKOV3 tumor growth [233] and was associated with decreased PD-1+ CD8+ T lymphocytes infiltration. The gene discussed is PDCD1; the disease is neoplasm.